• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cronos Expands Pre-Roll Portfolio with Spinach STIX®

    5/6/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CRON alert in real time by email

    TORONTO, May 06, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos"), an innovative global cannabis company, announced today that Spinach STIX®, its latest innovation in its popular line-up of Spinach® pre-rolls, is now available in more provinces across Canada. Spinach STIX® is the brand's first cylindrical-style pre-roll, designed to meet surging consumer interest in this highly sought-after format in the pre-roll category1.

    The pre-roll category remains one of the largest and most popular in the Canadian cannabis market, accounting for more than 33% of national retail dollar sales1. Nationally, the demand for cylindrical-style pre-rolls, which represented more than $17 million in Canadian retail sales in the pre-roll category in March 20261, is driven by consumer demand for pre-rolls that deliver a portable and compact design, an even and consistent burn, and a balanced, smooth smoking experience.

    "Introducing Spinach STIX® into more provinces across Canada allows us to meet evolving consumer preferences by offering an alternative, sleek pre-roll option for consumers to enjoy the strains they love most from our portfolio," said Mike Gorenstein, Chairman, President and CEO of Cronos. "We remain focused on optimizing our lineup of fantastic, high-quality products that have made Spinach® one of the top and most reliable cannabis brands in Canada."

    Spinach STIX® are available in the following curated selection of Cronos' top-performing strains:

    • Spinach STIX® GMO Cookies
      • The Spinach® brand's #1 flower strain, featuring sweet and savory flavor notes
      • Indica | THC: 25%+ | 10x0.4g
    • Spinach STIX® Sour Chem
      • Featuring classic gasoline, chemical, and zesty citrus notes

      • Sativa | THC: 26%+ | 10x0.4g
    • Spinach STIX® Space Cake
      • Featuring berry, nutty, and citrusy flavors
      • Hybrid | THC: 24%+ | 10x0.4g



    Spinach STIX® pre-rolls are available now in Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland, Nova Scotia, Ontario, and Saskatchewan. For more information and product availability, visit https://spinachcannabis.com/. To learn more about Spinach STIX® and to stay up-to-date on Spinach® products, follow @spinachwithfriends on Instagram.

    1Hifyre Retail Analytics - National Retail Dollars – March 2026

    About Cronos Group Inc. 

    Cronos is an innovative global cannabis company focused on scaling leading consumer goods products through R&D and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos' diverse international brand portfolio includes Spinach®, PEACE NATURALS®, LIT®, and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com. 



    Forward-looking Statements

    This press release may contain information that may constitute "forward-looking information" or "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, "Forward-looking Statements"). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about expanded availability of Spinach STIX® across Canadian provinces; continued consumer demand for cylindrical-style pre-rolls and the pre-roll category generally; anticipated consumer response to Spinach STIX® and its design attributes; the Company's intent to meet evolving consumer preferences through product format innovation; the Company's focus on expanding and refining the Spinach® product lineup; the continued positioning of Spinach® as a top and reliable cannabis brand in Canada; the Company's innovation strategy and development of high-quality consumer goods products; and Cronos' intention to build an international iconic brand portfolio and develop disruptive intellectual property by advancing cannabis research, technology and product development. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks. Financial results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, which has been filed on SEDAR+ and EDGAR and can be accessed at www.sedarplus.ca and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement. 

     

    For further information, please contact:

     

    Media Relations Contact:

    Emily Whalen

    Communications

    Tel: (416) 504-0004

    media.relations@thecronosgroup.com

     

    Investor Relations Contact:

    Harrison Aaron

    Investor Relations

    Tel: (416) 504-0004

    investor.relations@thecronosgroup.com



    Primary Logo

    Get the next $CRON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRON

    DatePrice TargetRatingAnalyst
    1/27/2026Buy
    Canaccord Genuity
    11/2/2022$3.00Mkt Perform
    Bernstein
    7/28/2022Hold → Buy
    Canaccord Genuity
    5/11/2022Neutral → Sector Outperform
    CIBC
    3/22/2022Underweight → Equal Weight
    Barclays
    3/7/2022$4.00 → $3.00Neutral
    Piper Sandler
    2/22/2022$7.00 → $4.25Sell
    Canaccord Genuity
    2/22/2022$7.00 → $4.00Neutral
    Piper Sandler
    More analyst ratings

    $CRON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cronos Expands Pre-Roll Portfolio with Spinach STIX®

    TORONTO, May 06, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos"), an innovative global cannabis company, announced today that Spinach STIX®, its latest innovation in its popular line-up of Spinach® pre-rolls, is now available in more provinces across Canada. Spinach STIX® is the brand's first cylindrical-style pre-roll, designed to meet surging consumer interest in this highly sought-after format in the pre-roll category1. The pre-roll category remains one of the largest and most popular in the Canadian cannabis market, accounting for more than 33% of national retail dollar sales1. Nationally, the demand for cylindrical-style pre-rolls, which represented mor

    5/6/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. to Hold Virtual 2026 Annual Meeting of Shareholders

    TORONTO, April 29, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2026 Annual Meeting of Shareholders on Thursday, June 18, 2026, at 11:00 a.m. ET. Cronos will be conducting the meeting in a virtual-only format via live audio webcast. Registered shareholders and duly appointed proxyholders will have an equal opportunity to participate in the 2026 Annual Meeting online regardless of their geographic location, including a chance to ask questions and vote. The Company's proxy statement describing the formal business to be conducted at the meeting and containing detailed instructions about how to participate in the meeting is ava

    4/29/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. to Hold 2026 First Quarter Earnings Conference Call on May 11, 2026

    TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2026 first quarter earnings conference call on Monday, May 11, 2026 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on th

    4/20/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Doucet Terrence Gregory Joseph converted options into 10,597 shares and covered exercise/tax liability with 5,199 shares, increasing direct ownership by 5% to 110,588 units (SEC Form 4)

    4 - Cronos Group Inc. (0001656472) (Issuer)

    5/14/26 4:58:49 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Wagner Adam converted options into 10,367 shares, increasing direct ownership by 11% to 103,987 units (SEC Form 4)

    4 - Cronos Group Inc. (0001656472) (Issuer)

    5/14/26 4:58:02 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Buggy Shannon converted options into 20,622 shares and covered exercise/tax liability with 9,179 shares, increasing direct ownership by 7% to 178,322 units (SEC Form 4)

    4 - Cronos Group Inc. (0001656472) (Issuer)

    5/14/26 4:57:28 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    SEC Filings

    View All

    SEC Form 10-Q filed by Cronos Group Inc.

    10-Q - Cronos Group Inc. (0001656472) (Filer)

    5/11/26 7:33:01 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Cronos Group Inc. (0001656472) (Filer)

    5/11/26 7:32:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form DEFA14A filed by Cronos Group Inc.

    DEFA14A - Cronos Group Inc. (0001656472) (Filer)

    4/24/26 4:41:31 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Cronos Group

    Canaccord Genuity initiated coverage of Cronos Group with a rating of Buy

    1/27/26 9:29:20 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Bernstein initiated coverage on Cronos Group with a new price target

    Bernstein initiated coverage of Cronos Group with a rating of Mkt Perform and set a new price target of $3.00

    11/2/22 6:32:18 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group upgraded by Canaccord Genuity

    Canaccord Genuity upgraded Cronos Group from Hold to Buy

    7/28/22 9:01:16 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Financials

    Live finance-specific insights

    View All

    Cronos Group Inc. to Hold 2026 First Quarter Earnings Conference Call on May 11, 2026

    TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2026 first quarter earnings conference call on Monday, May 11, 2026 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on th

    4/20/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. to Hold 2025 Fourth Quarter and Full-Year Earnings Conference Call on February 26, 2026

    TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 fourth quarter and full-year earnings conference call on Thursday, February 26, 2026 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be arch

    2/12/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. to Hold 2025 Third Quarter Earnings Conference Call on November 6, 2025

    TORONTO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 third quarter earnings conference call on Thursday, November 6, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay

    10/23/25 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Cronos Group Inc. (Amendment)

    SC 13D/A - Cronos Group Inc. (0001656472) (Subject)

    4/25/24 6:39:55 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Cronos Group Inc. (Amendment)

    SC 13D/A - Cronos Group Inc. (0001656472) (Subject)

    12/19/22 8:47:03 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Leadership Updates

    Live Leadership Updates

    View All

    Cronos Group Inc. Announces Results of 2025 Annual Meeting of Shareholders

    TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Friday, June 20, 2025 (the "Meeting"), shareholders holding a total of 276,989,452 common shares of the Company voted in person or by proxy, representing 71.87% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company's definitive proxy statement dated April 25, 2025 was elected as a director of the Company, with each director receiving in excess of 92.3% of the votes cast in favor of his or her election. The detailed results of the vote for the e

    6/23/25 5:30:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Appoints Anna Shlimak as Chief Financial Officer

    TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced the appointment of Anna Shlimak as Chief Financial Officer, effective today. Ms. Shlimak, who previously served as Cronos' Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition. Ms. Shlimak has been an integral part of Cronos' leadership team for the last seven years, playing a key role in shaping the Company's strategy, operational efficiencies, and engagement with the financial and

    3/19/25 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. Announces Results of Reconvened 2024 Annual Meeting of Shareholders

    TORONTO, July 22, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") announces that at its Annual Meeting of Shareholders (the "Meeting") reconvened July 19, 2024, approximately 98.6% of shareholders voting in person or by proxy approved the appointment of Davidson & Company LLP as the Company's independent auditor for fiscal year 2024 and authorized the Board of Directors of the Company to fix the independent auditor's remuneration. For complete results on all matters voted on at the Meeting, please see the Report of Voting Results filed on the Company's SEDAR+ profile at www.sedarplus.com and the Company's Form 8-K filed on EDGAR at www.sec.g

    7/22/24 4:15:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care